I prefer to look for GARP (growth at a reasonable price) stocks but also look for opportunities everywhere else. I don't have a specified time horizon. I invest in a stock for as long as my thesis holds true, and I get out when the facts change. In addition, I've developed market-beating algorithms with Python that have helped me find attractive investment opportunities within my own portfolio, and I have been investing since 2016.On top of that, I've worked at TipRanks as an analysis/news writer and even a ...

LOS ANGELES, Oct. 25, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Medpace reported its third quarter 2024 financial results on October 21, 2 ...

RADNOR, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ: MEDP) (“Medpace”). On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had ...

RADNOR, Pa., Oct. 23, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ: MEDP) ("Medpace").On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had seen ...

Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $533.3 million, representing a year-over-year increase of 8.3% [7][8] - Year-to-date revenue for the nine months ended September 30, 2024, was $1.57 billion, an increase of 13.3% [8] - EBITDA for Q3 2024 was $118.8 million, up 31.7% from $90.2 million in Q3 2023, with an EBITDA margin of 22.3% compared to 18.3% in the prior year [8][9] - Net income for Q3 2024 was $96.4 million, a 36.7% increase from $70.6 million in the prior year [9] - Full-year 2024 total revenue is expected to be in the range of $2.09 billion to $2.13 billion, representing growth of 10.8% to 12.9% over 2023 [10] Business Line Data and Key Metrics Changes - Net-new business awards entering backlog in Q3 decreased 12.7% year-over-year to $533.7 million, resulting in a net book-to-bill ratio of 1.0 [7][8] - Ending backlog as of September 30, 2024, was approximately $2.9 billion, an increase of 8.8% from the prior year [7] Market Data and Key Metrics Changes - RFPs were down modestly year-over-year and sequentially, but the quality of RFPs appears good [6][14] - The business environment remains decent despite elevated cancellations, with expectations for future growth [6] Company Strategy and Development Direction - The company aims to rebuild its pipeline of opportunities and expects book-to-bill numbers to approach a more usual range of greater than 1.15 in the second half of 2025 [6][10] - The company remains focused on its core business strategy, emphasizing biotech and full-service work, without pursuing large pharma contracts [59] Management's Comments on Operating Environment and Future Outlook - Management noted that elevated cancellations were primarily due to companies funded during the COVID high running out of money, rather than dissatisfaction with services [12][24] - The company anticipates that if cancellations return to normal levels, it can rebuild its pipeline and improve future backlog recognition [6][10] Other Important Information - The company generated $149.1 million in cash flow from operating activities in Q3 2024 [9] - As of June 30, 2024, the company had $656.9 million in cash and $308.8 million remaining under its share repurchase authorization program [9] Q&A Session Summary Question: Can you quantify the cancellations and their trends? - Management indicated that cancellations have been elevated across the board, primarily from companies that ran out of funding during the COVID high, with no specific trend across therapeutic areas [11][12] Question: What is the competitive environment like? - Management noted that while the environment is competitive, there has not been a trend toward aggressive pricing or irrational behavior among competitors [14][54] Question: What are the expectations for book-to-bill in Q4? - Management expects book-to-bill to be better than 1.0 but below 1.2, indicating a slight improvement from Q3 [36] Question: How much of the backlog is from the 2020-2021 vintage? - Management acknowledged that there is a portion of backlog from that period, but did not provide specific numbers [40] Question: What is the current headcount and employee growth outlook? - The company increased headcount by about 1.8% from the prior year and expects to maintain this level through Q4, with accelerated growth anticipated in 2025 [44][62] Question: What is the current backlog burn rate? - The burn rate has been consistent at 18.2% for the last three quarters, influenced more by bookings than by the progress of studies [66]

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock $0.01 par value MEDP NASDAQ Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT ...

Medpace Holdings, Inc. MEDP shares are trading lower on Tuesday after reporting its third-quarter financial results yesterday.Revenue rose 8.3% year-over-year to $533.3 million, missing the consensus of $540.99 million.On a constant currency basis, revenue increased by 8.1% in the quarter. As of September 30, backlog rose by 8.8% to $2.927 billion.Net new business awards totaled $533.7 million for the third quarter of 2024, resulting in a net book-to-bill ratio of 1.00x, compared to $611.5 million in the pr ...

Medpace (MEDP) came out with quarterly earnings of $3.01 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.22 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 8.66%. A quarter ago, it was expected that this provider of outsourced clinical development services would post earnings of $2.52 per share when it actually produced earnings of $2.75, delivering a surprise of 9.13%. Over ...

Revenue Performance - Revenue for Q3 2024 was $533.3 million, an increase of 8.3% from $492.5 million in Q3 2023, with a backlog conversion rate of 18.2%[2] - Year-to-date revenue for 2024 was $1,572.5 million, reflecting a 13.3% increase from the prior year[7] - Full year 2024 revenue is forecasted to be between $2.090 billion and $2.130 billion, indicating growth of 10.8% to 12.9% over 2023[9] - Net revenue for the three months ended September 30, 2024, was $533,317,000, representing a 8.3% increase from $492,499,000 in the same period of 2023[19] Profitability Metrics - GAAP net income for Q3 2024 was $96.4 million, or $3.01 per diluted share, compared to $70.6 million, or $2.22 per diluted share in Q3 2023, with a net income margin of 18.1%[5] - Net income for the nine months ended September 30, 2024, was $287,368,000, up 40.4% from $204,512,000 in the same period of 2023[19] - Basic net income per share attributable to common shareholders for the three months ended September 30, 2024, was $3.11, compared to $2.30 for the same period in 2023, reflecting a 35.2% increase[19] - Full year 2024 GAAP net income is projected to be between $376.0 million and $388.0 million[9] Cash Flow and Liquidity - Cash and cash equivalents were $656.9 million as of September 30, 2024, with $149.1 million generated in cash flow from operating activities during Q3 2024[8] - Cash and cash equivalents rose significantly to $656,900,000 as of September 30, 2024, compared to $245,449,000 at the end of 2023, indicating a 167.5% increase[21] Backlog and Business Awards - Net new business awards in Q3 2024 were $533.7 million, a decrease of 12.7% from $611.5 million in Q3 2023, resulting in a net book-to-bill ratio of 1.00x[4] - Backlog as of September 30, 2024, increased by 8.8% to $2,927.4 million from $2,689.5 million in the prior year[4] Operating Expenses and EBITDA - EBITDA for Q3 2024 increased by 31.7% to $118.8 million, representing an EBITDA margin of 22.3%, compared to $90.2 million and 18.3% in Q3 2023[5] - EBITDA for the nine months ended September 30, 2024, was $346,672,000, compared to $266,663,000 for the same period in 2023, reflecting a 30.0% increase[26] Shareholder Equity and Repurchase Program - Total shareholders' equity rose to $881,439,000 as of September 30, 2024, compared to $558,950,000 at the end of 2023, indicating a 57.7% increase[22] - The company had $308.8 million remaining under its authorized share repurchase program as of September 30, 2024[8] Advanced Billings - Advanced billings increased to $670,939,000 as of September 30, 2024, from $559,860,000 at the end of 2023, showing a 19.8% growth[21]

Medpace (MEDP) closed the most recent trading day at $343.05, moving +1.57% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.9%. Meanwhile, the Dow gained 0.81%, and the Nasdaq, a tech-heavy index, added 1.22%. The provider of outsourced clinical development services's shares have seen a decrease of 2.78% over the last month, surpassing the Medical sector's loss of 4.05% and falling behind the S&P 500's gain of 3.15%. Market participants will be close ...